Interpretation and Elaboration for the ARRIVE Guidelines 2.0—Animal Research: Reporting In Vivo Experiments (V)
10.12300/j.issn.1674-5817.2023.146
- VernacularTitle:《动物研究：体内实验报告》即ARRIVE 2.0指南的解释和阐述（五）
- Author:
Zhengwen MA
1
;
Xiaying LI
2
;
Xiaoyu LIU
3
;
Yao LI
1
;
Jian WANG
1
;
Jin LU
1
;
Guoyuan CHEN
4
;
Xiao LU
5
;
Yu BAI
6
;
Xuancheng LU
7
;
Yonggang LIU
8
;
Yufeng TAO
9
;
Wanyong PANG
10
Author Information
1. Department of Laboratory Animal Science, School of Medicine, Shanghai Jiao Tong University, Shanghai 200025, China
2. Peking University, School of Life Science, laboratory research Center, Beijing 100871, China
3. National Institute for Occupational Health and Poison Control, Beijing 100050, China
4. Center for Excellence in Molecular Cell Science, Chinese Academy of Science, Shanghai 200031, China
5. Dizal Pharmaceuticals Co., Ltd. , Shanghai 201203, China
6. Novo Nordisk Research Centre China, Beijing 102206, China
7. National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases (NITFID), Chinese Center for Disease Control and Prevention, Beijing 102206, China
8. Harbin Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Harbin 150001, China
9. China National Accreditation Service for Conformity Assessment, Beijing 100062, China
10. Translational in Vivo Model Research Platform, Sanofi G&D, Beijing 100022, China
- Publication Type:Journal Article
- Keywords:
Animal experiment;
ARRIVE 2.0 guidelines;
ARRIVE Recommended set;
Pain management;
Animal care and monitoring
- From:
Laboratory Animal and Comparative Medicine
2024;44(1):105-114
- CountryChina
- Language:Chinese
-
Abstract:
Improving the reproducibility of biomedical research results is a major challenge. Transparent and accurate reporting of the research process enables readers to evaluate the reliability of the research results and further explore the experiment by repeating it or building upon its findings. The ARRIVE 2.0 guidelines, released in 2019 by the UK National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), provide a checklist that is applicable to any in vivo animal research report. These guidelines aim to improve the standardization of experimental design, implementation, and reporting, as well as enhance the reliability, repeatability, and clinical translation of animal experimental results. The use of the ARRIVE 2.0 guidelines not only enriches the details of animal experimental research reports, ensuring that information on animal experimental results is fully evaluated and utilized, but also enables readers to understand the content expressed by the author accurately and clearly, promoting the transparency and completeness of the fundamental research review process. At present, the ARRIVE 2.0 guidelines have been widely adopted by international biomedical journals. This article is based on the best practices following the ARRIVE 2.0 guidelines in international journals, and it interprets, explains, and elaborates in Chinese the fifth part of the comprehensive version of the ARRIVE 2.0 guidelines published in PLoS Biology in 2020 (the original text can be found at https://arriveguidelines.org). This section includes the items 6-11 of Recommended 11 section, covering "Animal Care and Monitoring", "Interpretation/Scientific Implications", "Generalisability/Translation", "Protocol Registration", "Data Access" and "Declaration of Interests". Its aim is to promote a comprehensive understanding and use of the ARRIVE 2.0 guidelines among domestic researchers, to enhance the standardization of experimental animal research and reporting, and to promote high-quality development of experimental animal sciences and comparative medicine research in China.
